Trials / Unknown
UnknownNCT05381506
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
A Phase II, Prospective, Multicenter Study Ofrelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib and Gemox | Drug: Orelabrutinib Orelabrutinib 200mg, po, qd Drug: Gemox14 Gemcitabine, Oxaliplatin |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-12-01
- Completion
- 2025-12-01
- First posted
- 2022-05-19
- Last updated
- 2022-07-08
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05381506. Inclusion in this directory is not an endorsement.